Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
AssigneeGeron Corporation
InventorsMonic J. Stuart, Stephen Kelsey
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.
Claims10
A method for treating myelodysplastic syndrome (MDS) in a human, the method comprising:
- administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human, wherein the human has transfusion-dependent anemia and wherein the administering is effective to treat MDS in the human.
A method for treating myelodysplastic syndrome (MDS) in a human, the method comprising:
- administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human every four weeks, wherein the human has transfusion-dependent anemia and wherein the administering is effective to treat MDS in the human.
A method for alleviating at least one symptom associated with myelodysplastic syndrome (MDS) in a human in need thereof, the method comprising administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human, wherein administration of the imetelstat alleviates at least one symptom associated with MDS.
Dependencies are inferred from the claim text.